| ADTX 0.01 127.27% | GDC 0.0181 -15.02% | SOXS 3.59 -19.51% | GPUS 0.359 -9.78% | SRXH 0.1245 -37.59% | BITO 8.56 -1.95% | TZA 4.02 -5.85% | SPCX 185 -3.56% | MRVL 310.58 7.27% | CDT 1.02 47.19% | NVDA 210.69 2.95% | INTC 133.99 10.64% | WKSP 0.7379 23.33% | INLF 0.1566 -64.20% | NOK 13.49 -2.46% | AAL 15.99 3.70% | AZTR 0.1717 -15.42% | CAST 8.07 56.70% | CRVO 4.24 11.29% | NFLX 77.38 0.55% | AMC 2.83 6.39% | QS 8.04 16.52% | FLEX 147.61 3.13% | GRAB 3.57 3.48% | SOFI 17.91 2.81% | YYGH 0.0803 -37.70% | AAPL 298.01 0.70% | ATPC 3.88 42.12% | RKLB 107.24 -0.69% | BAC 56.2 -0.58% | LNKS 2.68 67.50% | SMCI 30.66 10.37% | PFE 25.22 -2.70% | SPY 746.74 0.78% | RIG 5.31 -4.84% | AMZN 244.39 2.90% | PLUG 2.85 7.55% | CRWV 117.95 2.38% | TSLL 13.16 1.86% | ONDS 9.27 1.64% | CMCSA 22.43 -1.15% | MU 1133.99 8.70% | TQQQ 82.87 6.87% | BFLY 8.9 55.87% | NVD 4.75 -5.57% | SQQQ 36.75 -7.01% | MSFT 379.4 0.13% | CTSH 43.7 -10.49% | WPRT 2.26 21.51% | T 22.01 -1.92%

Comparative Analysis of Pharmaceutical Companies on NASDAQ

Traws Pharma, Inc. (NASDAQ:TRAW) is a pharmaceutical company currently trading at $1.61. However, with a target price of $0.73, it faces a potential downside of approximately -54.90%. This significant negative growth potential has led investment analysts to exclude Traws from coverage, reflecting a pessimistic outlook on the stock.

In comparison, Imunon, Inc. (IMNN) presents a more optimistic scenario. With a current price of $3.80 and a target price of $5.36, Imunon has a growth potential of +41.18%. Despite a negative earnings per share (EPS) of -12.53 and a price-to-earnings (P/E) ratio of -0.68, its market cap stands at $9.58 million, indicating investor interest.

Cocrystal Pharma, Inc. (COCP) is another peer, trading at $1.11 with a target price of $0.79, suggesting a growth potential of -28.68%. Its market cap is $11.38 million, with an EPS of -0.93 and a P/E ratio of -1.17, reflecting challenges similar to Traws.

Mustang Bio, Inc. (MBIO) trades at $1.09 with a target price of $0.97, resulting in a growth potential of -10.76%. With a market cap of $7.96 million, an EPS of -6.71, and a P/E ratio of -3.44, it faces moderate challenges compared to its peers.

Published on: January 14, 2026